INTRODUCTION
============

Familial hypercholesterolaemia is an autosomal dominant disorder, characterized clinically by elevated LDL-cholesterol (LDL-C) levels, and as a consequence premature mortality and morbidity from coronary heart disease (CHD). There is a 50% risk of CHD in a man with familial hypercholesterolaemia by the age of 50 years and in a woman with familial hypercholesterolaemia by the age of 60 years, which has been reported in several studies, as previously summarized \[[@R1]\]. Once identified, individuals with heterozygous familial hypercholesterolaemia can be successfully treated by lipid-lowering agents particularly statins which reduce their CHD mortality to that of the general population. Familial hypercholesterolaemia affects about one of 500 \[[@R2]\] to one of 200 \[[@R3],[@R4]^▪▪^\] individuals of the Caucasian population, with therefore between 120 000 and 240 000 people in the UK with heterozygous familial hypercholesterolaemia, and an estimated 1.8--4.5 million people affected in Europe, of whom at least 75% are undiagnosed \[[@R2]\]. Cascade testing, using the family mutation to identify carrier relatives unambiguously, is a cost-effective method of finding additional familial hypercholesterolaemia patients, and has been used extensively in some countries in Europe, most notably in Holland, with great success \[[@R5]\]. In 2008, the UK agency NICE published an familial hypercholesterolaemia guideline for implementing genetic testing of index case and cascade testing of their relatives on the basis of compelling evidence of clinical efficacy and cost-effectiveness \[[@R6]\], and several other country specific and international consensus guidelines have made similar recommendations \[[@R7]\]. Using the NICE model, it has been estimated that DNA-based cascade testing for identifying and managing affected relatives had an incremental cost-effectiveness ratio (ICER) of ∼£3666 (∼€4600) per quality adjusted life year (QALY) gained \[[@R8]\], which is much more cost-effective than many current ongoing screening programmes. However, in the UK and many countries in Europe, DNA-based cascade testing is still not being undertaken, in large part because of the perception that the provision of the service is too expensive in difficult economic times. Here, we review the literature regarding the cost-effectiveness of DNA-based cascade testing for familial hypercholesterolaemia and examine how recent advances in genetic knowledge and methods, and the cost reduction achieved by changing the model of care and using off-patent statins can influence overall costs.  
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GENETIC TESTING FOR FAMILIAL HYPERCHOLESTEROLAEMIA
==================================================

Roughly, 93% of patients with identified genetic cause have a mutation in the receptor for LDLs (*LDLR*) and the University College London worldwide database currently holds more than 1200 published and confirmed genetic causes of familial hypercholesterolaemia \[[@R9]\]. The second most common cause of familial hypercholesterolaemia worldwide is a single mutation in the gene for apolipoprotein B (*APOB*) which prevents efficient binding of the LDL-C particle to the receptor and therefore reduces clearance of LDL-C from the blood by the liver (∼5% of familial hypercholesterolaemia patients in the UK \[[@R10]\]). The other molecular cause of familial hypercholesterolaemia is that of mutations in the gene for proprotein convertase subtilisin/kexin type 9 (*PCSK9*), which encodes the PCSK9 protein which is involved in the degradation of the LDL-receptor during its recycling and cellular trafficking. Mutations causing familial hypercholesterolaemia are gain-of-function, and in the UK a common mutation in this gene explains about 2% of patients with familial hypercholesterolaemia \[[@R10]\].

Since the announcement of the entire human genome sequence in 2007 there has been huge technological advances, such that it is now possible to use 'next-generation sequencing' (NGS) methods to sequence the whole of the genome of an individual, or more usefully, all the parts of the genome that code for proteins, known as 'exome sequencing' \[[@R11],[@R12],[@R13]^▪▪^,[@R14]\]. DNA diagnostic labs have now developed methods whereby all the protein coding regions of the genome for the known familial hypercholesterolaemia genes can be captured and sequenced in one run with high accuracy \[[@R15]^▪▪^,[@R16],[@R17]\], and with the addition of small 'barcoding' sequence runs into the primers used to PCR amplify the regions of interest, it is now possible to mix the samples from up to 96 individuals and analyse them in one run with high accuracy \[[@R17]\]. This economy of scale is helping to drive down prices so that now a full familial hypercholesterolaemia diagnostic scan can be completed for roughly £250 and the data can also be used to look to see if an individual has a large insertion or deletion of the gene, which occurs in about 5% of patients \[[@R15]^▪▪^\]. Using these methods produces a large amount of sequence data, which must be analysed using statistical and bioinformatics approaches and this has increased the number of occasions whereby a variant of uncertain significance is identified \[[@R18]^▪▪^\]. This creates a diagnostic conundrum which clearly cannot be reported as familial hypercholesterolaemia-causing to the clinician or patient but which requires either in-vitro molecular assays to examine impact on transcription or correct splicing, or by family studies to see if other relatives who have inherited this variant have also shown high LDL-C levels. Several novel variants in the *APOB* gene have also been identified and shown to be familial hypercholesterolaemia-causing using in-vitro assays \[[@R19],[@R20]^▪▪^\].

POLYGENIC FAMILIAL HYPERCHOLESTEROLAEMIA
========================================

Overall, ∼60% of patients with a clinical diagnosis of possible or definite familial hypercholesterolaemia (i.e. having a Dutch Lipid Clinic Score of over 5) are mutation negative by conventional testing, and in this group it is now clear that the familial hypercholesterolaemia phenotype can be reproduced by an accumulation of common small-effect LDL-C raising alleles. This was first reported in 2013 \[[@R21]\], and now (Fig. [1](#F1){ref-type="fig"}) confirmed in samples from an additional six different countries and in both adults and children \[[@R22]^▪▪^\]. The data indicate that in clinical familial hypercholesterolaemia but mutation-negative patients, at least 80% are likely to have a polygenic cause of the elevation in LDL-C rather than an as yet unidentified single gene mutation. Cascade testing would be less effective in such cases, since the number of them inheriting this high number of LDL-raising single nucleotide polymorphisms (SNPs) would be considerably lower than the 50% affected relatives expected for monogenic inheritance. We proposed \[[@R21]\] that patients with a familial hypercholesterolaemia phenotype, in whom no familial hypercholesterolaemia-causing mutation can be found, should be given the clinical diagnosis of polygenic hypercholesterolaemia, and not familial hypercholesterolaemia. This should not, however, affect the treatment of these patients, but would influence the decision to conduct cascade testing in their relatives \[[@R21]\].
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CLINICAL UTILITY OF DNA TESTING
===============================

There are several reasons why, based on published evidence, the NICE guidelines for familial hypercholesterolaemia published in 2008, and the NICE quality standards, published in 2013 emphasized the clinical utility of DNA testing. The first is because there is a significant overlap in the distribution of LDL-C levels in mutation carriers and their first-degree relatives who do not carry a mutation \[[@R23],[@R24]\], and this overlap reduces the efficiency of cascade testing. The cascade testing programmes that have been carried out so successfully in Holland \[[@R5],[@R24]\] and that are now being actively pursued in both Wales \[[@R25]\] and Scotland \[[@R26]\], therefore use DNA testing to identify those with a mutation and only cascade test in mutation-positive families. Although false-positive results based on LDL-C levels identify individuals whose LDL-C is high and may need to be treated, if they do not carry the family mutation, testing their children will clearly result in no (or very low) frequency of new familial hypercholesterolaemia patients. The opposite of this is that in the false-negative individuals who carry a mutation but whose LDL-C level is a below the diagnostic threshold, their low LDL-C may be because they have luckily inherited LDL-C lowering genetic variants or are adopting an LDL-C lowering environment, but clearly 50% of their children are at risk of inheriting the mutation and may not be lucky enough to take on the lifestyle or have inherited the LDL-C-lowering variants.

COST-EFFECTIVENESS OF DIFFERENT STRATEGIES FOR CASCADE TESTING IN FAMILIAL HYPERCHOLESTEROLAEMIA FAMILIES
=========================================================================================================

The cost-effectiveness literature for familial hypercholesterolaemia has been recently reviewed \[[@R27]\]. Six studies reported on the cost-effectiveness of familial hypercholesterolaemia screening and subsequent treatment of the identified relatives. All such papers use published estimates of the high risk of CHD in men and women with familial hypercholesterolaemia (as summarized in \[[@R1]\]), and the efficacy of the early-in-life initiated treatment, as has been demonstrated in the UK Simon Broome Study and in Holland \[[@R28],[@R29]\]. These CHD estimates were examined in detail by NICE CG71 and accepted as robust and used in their published analysis \[[@R8]\]. Compared with no screening the ICER of screening ranged from €3177 to €29 554 per life year gained. The results were sensitive to the underlying prevalence of familial hypercholesterolaemia among the population being examined, the validity of the screening test and the price and efficacy of lipid-lowering therapy. The authors concluded that overall, cascade testing for new cases of familial hypercholesterolaemia was cost-effective, but there were uncertainties in the modelling methods, especially with regard to the use of different approaches to assess the outcomes of treatment. It was recognized that cost-effectiveness would improve further once atorvastatin and rosuvastatin lost exclusivity.

These issues were examined in more detail in a follow-up paper \[[@R30]^▪▪^\] using data from an Australian healthcare perspective. Using a Markov model and a 10-year time horizon to simulate the onset of first-ever CHD and death in close relatives of monogenetic familial hypercholesterolaemia index cases the decision-analysis compared the clinical consequences and costs of cascade testing versus no testing. The annual risk of CHD and benefits of treatment were estimated from a cohort study, and the underlying prevalence of familial hypercholesterolaemia, sensitivity, specificity, cost of screening, treatment and clinic follow-up visits were derived from a cascade screening service for familial hypercholesterolaemia in Western Australia. The model was cost-effective. It estimated that testing would reduce the 10-year incidence of CHD from 50.0 to 25.0% among people with familial hypercholesterolaemia. Of every 100 people tested, there was an overall gain of approximately 25 life-years and 29 QALY, with an ICER in Australian dollars, \$4155 (€5850) per years of life saved and \$3565 (€5093) per QALYs gained.

A recent paper by Pears *et al.*\[[@R31]^▪▪^\] examined the cost-effectiveness of three alternative models of care for familial hypercholesterolaemia. The first model considered was a specialist-led model. This model was similar to the NICE model with the exception that a lower proportion of patients would have annual reviews in secondary care. The second model involved primary care taking responsibility for the entire adult familial hypercholesterolaemia care pathway. In this model, no patients would be referred to a familial hypercholesterolaemia specialist (locally this means a lipidologist), and all patients would be reviewed annually by their GP. The final model was a 'dual care' model in which primary care would manage the majority of the familial hypercholesterolaemia cascade testing pathway. In this final model, GPs would be able to refer patients to lipidologists if they needed further advice about management, or to genetic services, when advice on cascade testing was needed because a genetic mutation had not been identified.

The authors conclude that costs for all three models were now less than 50% of the cost of the original estimates undertaken by NICE. By using the latest statin costs and reduced DNA testing costs, by reducing the proportion of patients prescribed more expensive proprietary owned rosuvastatin and by managing more patients with familial hypercholesterolaemia in primary care, providing an familial hypercholesterolaemia service is now much more affordable than predicted by NICE in 2008. The reduction in costs with generic atorvastatin now available (∼£368--25 pa for 40 mg or £45 pa for 80 mg) this reduces the cost of a 10-year service by 42.5% (∼£4.8--2.8 million). Compared with the generic atorvastatin costing estimates, the specialist-led model reduced 10-year costs by a further 27.2%, the dual care model by a further 32.5% and the GP-led model by a further 35.8%. The three alternative models of care were now less than 50% of the cost of the original estimates undertaken by NICE. If 50% of patients with familial hypercholesterolaemia are diagnosed early in life and then treated optimally over a 55-year period, £94.7 million (£1.97 million per 1000 cases) can be saved through reduced CV events, or £1.7 million (€1.2 million) per year.

Pears *et al.* assess their models in a population of 1.95 million, estimating the dual care model to cost £1.89 million (∼€2.6 million) over 10 years. If we extrapolate the figure to that of the entire population of England (53.9 million in 2013), the original NICE model will cost approximately £134.5 million (€95.49 million) over 10 years and the dual care model will cost approximately £67.3 million (€47.8 million). Such a programme would include the cost of medicines, management in primary care, referral for specialist attention and genetic testing and assessment of family members. However, as we now understand that the majority of those with no detectable mutation do not have 'monogenic' familial hypercholesterolaemia, costs can be reduced further if we also only cascade test from familial hypercholesterolaemia patients with a monogenic cause of familial hypercholesterolaemia. Based on (31) this would be only approximately 45% of those with a clinical diagnosis of familial hypercholesterolaemia, and would reduce costs still further to approximately £28.5 million (∼€40 million) as shown in Fig. [2](#F2){ref-type="fig"}a (see \[[@R28]\] and supplementary material for detailed assumptions of this model). The dual model of care, excluding polygenic hypercholesterolaemia cascade testing, is now less than 25% of the cost of the original 2008 estimates undertaken by NICE. Restricting cascade testing to monogenic families reduces the number of cardiac events avoided over 10 years from 2736 to 2229 (18.5% reduction) as shown in Fig. [2](#F2){ref-type="fig"}b. However, relative cost-effectiveness jumps. For instance, in year eight onwards the cost per cardiac event avoided is £39 489 (€28 037) in the original NICE model, £18 088 (€12 842) in the dual model and £7 155 (€5080) in the monogenic cascade testing model.
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CONCLUSION
==========

Although almost all recent guidelines for the identification and management of familial hypercholesterolaemia recognize the utility of DNA-based cascade testing for the identification of at-risk relatives, few countries to date have implemented this as a national strategy. The advent of NGS methods and the recognition that the vast majority of patients with a clinical diagnosis of familial hypercholesterolaemia but with no identified mutation have a polygenic cause of their elevated LDL-C suggests sensible targeting strategies for cascade testing. It is likely that individuals with polygenic familial hypercholesterolaemia will not have so severe atherosclerosis as monogenic familial hypercholesterolaemia, or at least will not manifest their cardiovascular disease at such an early age, although further research is urgently needed to explore this. Such individuals could be easily managed in general practice, whereas monogenic familial hypercholesterolaemia may well require management in expert centres because they require multiple drug therapies in order to reduce their LDL-C levels to acceptable target levels, or the use of novel lipid lowering agents such as monoclonal antibodies to PCSK9. Use of this dual care approach also reduces overall costs of the cascade testing and management programme, but the major factor in the huge reduction in costs is the availability of potent off-patent statins. As such, the cost of providing a familial hypercholesterolaemia service has reduced by three-quarters in the past 5 years.
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